Latest filing published 28 Apr 2026 for Abbott Laboratories.
Based on 62 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Daniel J. Starks has a buyer's record: 62 purchases against 13 sales, which puts 83% of market trades on the buy side. The 62 purchases, all at Abbott Laboratories, total EUR 5.2 million, with a median of EUR 32,040; the largest are from April 27, 2026 (EUR 790,327) and February 4, 2026 (EUR 461,424 and EUR 458,773). Of these 62 purchases with a stored 90-day result, the median is 5.6%, with 97% positive (stored past results, not a forecast). The 13 sales total EUR 30.3 million, with a median of EUR 2,389,385, the largest (EUR 4,691,193) dated May 2, 2023.
The record has 97 filings between December 14, 2016 and April 28, 2026: 88 at Abbott Laboratories (Director) and 9 at St Jude Medical Inc (Chairman, CEO & President). The year 2018 holds 60 of them. Four filings fall in the last 12 months, 3 of them purchases. Filings are published a median of 1 day after the trade.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 97 declarations